Day: January 23, 2024

American National Bankshares Reports Fourth Quarter and Full Year 2023 Earnings

Written by Customer Service on January 23, 2024. Posted in Earnings Releases And Operating Results.

DANVILLE, Va., Jan. 23, 2024 (GLOBE NEWSWIRE) — American National Bankshares Inc. (NASDAQ: AMNB) (“American National” or the “Company”) today reported fourth quarter 2023 earnings of $4.0 million, or $0.38 per diluted common share. Those results compare to earnings of $8.0 million, or $0.76 per diluted common share, during the same quarter in the prior year, and earnings of $5.8 million, or $0.54 per diluted common share, for the third quarter of 2023. Earnings for the twelve months ended December 31, 2023, were $26.2 million, or $2.46 per diluted common share, compared to $34.4 million, or $3.23 per diluted common share, for the same period of 2022. Earnings for the fourth quarter and twelve months ended December 31, 2023, reflect the impact of merger related expenses of $875 thousand and $2.6 million in connection with the Company’s...

MKS Instruments Announces Fourth Quarter and Full Year 2023 Earnings Conference Call

Written by Customer Service on January 23, 2024. Posted in Public Companies.

ANDOVER, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that the Company will release fourth quarter and full year 2023 financial results after market close on Wednesday, February 7, 2024. A conference call with management will be held on Thursday, February 8, 2024 at 8:30 a.m. (Eastern Time). A live and archived webcast of the call will be available on the company’s website at https://investor.mks.com/. To participate in the call by phone, participants should register online by clicking here, where dial in details will be provided. We encourage participants to register and dial in to the conference call at least 15 minutes before the start of the call to ensure a timely connection. About MKS Instruments MKS Instruments...

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Written by Customer Service on January 23, 2024. Posted in Public Companies.

REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism (HI). The Innovation Passport designation was granted based on the substantial unmet medical need in this condition and the potential for RZ358 to benefit patients as evidenced by the Phase 2 RIZE study in congenital HI, which safely demonstrated significant improvements in hypoglycemia events. The Innovation Passport designation in the U.K. is the entry point to the Innovative...

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections

Written by Customer Service on January 23, 2024. Posted in Public Companies.

Phase I/II trial assessing the safety and efficacy of RECCE® 327 (R327), a broad-spectrum anti-infective as a topical treatment, met all primary endpoints R327 was well-tolerated in all patients, resolving mild skin and soft tissue diabetic foot infections (DFI), including multidrug-resistant Gram-positive and Gram-negative pathogens Data supports imminent domestic and international site expansionSYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a Phase I/II trial assessing the safety and efficacy of its lead synthetic anti-infective candidate, RECCE® 327 (R327), in patients with diabetic foot infections (DFI). “We are pleased that the Phase I/II clinical trial...

Enphase Energy Announces Conference Call to Review Fourth Quarter and Full Year 2023 Financial Results Tuesday, Feb. 6, 2024 at 4:30 p.m. Eastern Time

Written by Customer Service on January 23, 2024. Posted in Public Companies.

FREMONT, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, announced today that it will host a conference call and webcast on Tuesday, Feb. 6, 2024 at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results for the period ended Dec. 31, 2023. The live webcast can be accessed on the Enphase Energy Investor Relations website at investor.enphase.com, and a recorded version of the call will also be available there approximately one hour after the call.What: Enphase Energy’s Fourth Quarter and Full Year 2023 Financial Results Earnings Conference Call and Webcast Date: Tuesday, Feb. 6, 2024 Time: 4:30 p.m. Eastern Time Live...

Genasys Inc. Schedules Fiscal First Quarter 2024 Financial Results and Conference Call for February 13, 2024

Written by Customer Service on January 23, 2024. Posted in Public Companies.

SAN DIEGO, Jan. 23, 2024 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in protective communications, today announced plans to release financial results for its fiscal first quarter, ended December 31, 2023, after the market close on Tuesday, February 13, 2024. A conference call to discuss the fiscal first quarter 2024 financial results will be held at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Conference call details: Date: February 13, 2024Time: 4:30 p.m. Eastern / 1:30 p.m. Pacific Toll-Free Dial-In Number: (888) 390-3967 (U.S. & Canada)International Dial-In Number: (862) 298-0702Webcast: https://www.webcaster4.com/Webcast/Page/1375/49779 Please dial in 10 minutes prior to the start time and tell the operator you are calling in for the Genasys Fiscal First Quarter 2024 Financial Results Call. Questions...

InnovAge to Announce Fiscal Second Quarter 2024 Financial Results and Host Conference Call Tuesday, February 6, 2024

Written by Customer Service on January 23, 2024. Posted in Public Companies.

DENVER, Jan. 23, 2024 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced it will release its 2024 fiscal second quarter financial results on Tuesday, February 6, 2024, after market close. In conjunction, the Company will host a conference call to review the results at 5 p.m. E.T. Conference Call DetailsA live audio webcast of the call will be available on the Company’s website, https://investor.innovage.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access...

Cerence to Announce Fiscal First Quarter Results on February 6, 2024

Written by Customer Service on January 23, 2024. Posted in Public Companies.

BURLINGTON, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, will announce its first quarter financial results for the quarter ended December 31, 2023 on Tuesday, February 6, 2024 at 7:00 a.m. Eastern Time / 4:00 a.m. Pacific Time. The company will host a live conference call and webcast, with accompanying slides, to discuss the results on the same day at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Interested investors and analysts are invited to join the audio conference call by registering here. Webcast access will be available in the Investor Information section of the company’s website at www.cerence.com. The teleconference replay will be available through February 20, 2024. The webcast replay will be available on the Company’s website at www.cerence.com. To learn more about...

Pulse Oil Announces Closing of Rights Offering

Written by Customer Service on January 23, 2024. Posted in Public Companies.

CALGARY, Alberta, Jan. 23, 2024 (GLOBE NEWSWIRE) — Pulse Oil Corp. (the “Company” or “Pulse”) (TSXV: PUL) reports the completion of the rights offering (the “Rights Offering”) to eligible holders of its common shares (the “Common Shares”), announced in its news release of December 7, 2023. Pursuant to the Rights Offering, the Company issued a total of 103,910,942 Common Shares, the full amount of the Rights Offering, at a price of $0.04 per Common Share for aggregate gross proceeds of $4,156,437.68. A total of 49,074,871 Common Shares were issued under the basic subscription privilege, including 39,889,286 Common Shares to insiders of the Company, as a group, and 6,786,000 Common Shares to all other persons (“Non-Insiders”), as a group. In addition, a total of 2,399,585 Common Shares were issued under the additional subscription...

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

Written by Customer Service on January 23, 2024. Posted in Public Companies.

MINNEAPOLIS, MN, Jan. 23, 2024 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application related to the Company’s proprietary biomaterials and corresponding products. The broad scope of the issued claims in this patent, entitled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof” provides protection for a broad range of proprietary products, including the biocompatible sponge-like particles used in PetVivo’s signature product, Spryng™ with OsteoCushion™ Technology. “We are...

Day: January 23, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals